Tema Sinergie

About Tema Sinergie

Tema Sinergie is a Hot Cells & Shielding company; the kind of vendor BD teams should have a 15-minute conversation with at SNMMI.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Endpoints News · 2026-12-01
  Tema Sinergie signs supply agreement to support late-stage trials
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Reuters Health · 2026-03-22
  Tema Sinergie appoints new Chief Medical Officer ahead of pivotal trial
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• BioPharma Reporter · 2026-06-11
  Tema Sinergie announces Phase II readout for lead theranostic candidate
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• FierceBiotech · 2026-09-08
  Tema Sinergie expands cyclotron capacity to meet Lu-177 demand
  The work builds on more than a decade of radiochemistry collaboration.
• STAT News · 2026-12-17
  Tema Sinergie partners with academic center on Actinium-225 program
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.